Get the free version of Marbridge Daily delivered to your inbox

Click here to subscribe

Pharmacy E-tailer 7Lekang Completes USD 9-digit Series B

Iyiou, 11/05/15

Guangzhou-based Qilekang Pharmaceutical Chain, operator of online B2C pharmacy platform 7Lekang, recently announced that it completed USD 9-digit Series B funding in October from undisclosed investors. In August, 7Lekang CEO Shi Zhenyang said that Series B funding would be used to recruit doctors, pay doctor service fees, and subsidize patients' medical purchases.

Qilekang Pharmaceuticals, established in 2001, currently operates 9 pharmacy outlets in Guangzhou. It began B2C pharmacy e-commerce operations in 2011. In 2014, Qilekang's online pharmacy sales totaled RMB 771 mln. According to data from Tmall Drugstore, the pharmaceutical channel operated by Chinese e-commerce conglomerate Alibaba Group (NYSE: BABA), Qilekang's monthly sales in September 2015 were RMB 38 mln, of which sales through the 7Lekang platform, Tmall Drugstore, and B2C e-commerce platform JD.com (Nasdaq: JD) amounted to RMB 10 mln, 21 mln, and 7 mln, respectively.

In August 2015, CEO Shi Zhenyang announced that the company would launch a mobile health management app called "Dabai Yunzhen."

Editor's Note: 7Lekang's Dabai Yunzhen app, currently available on leading app stores, allows doctors to manage patient information and appointment times.

Keywords: Shi Zhenyang e-commerce Internet funding B2C Series B Qilekang 7Lekang online healthcare mobile healthcare mobile application Dabai Yunzhen

Feedback

Please note, all fields are required.
None of your personal information will be shared with third parties.

SendingSending

Disclaimer

The information contained in this newsletter is based upon sources that Marbridge Consulting believes to be reliable, and we have made every effort to translate the original articles or article excerpts as faithfully as possible. However, Marbridge Consulting makes no warranty of and assumes no legal responsibility for the accuracy of either the original source material or the English language translations.

Marbridge Daily Premium

Interested in gaining full access to all newsletter articles and the Marbridge Daily archive? To learn more about premium subscription options, including pricing, please:

Click here

Marbridge Consulting RSS Feed

Marbridge Reports